Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 611,188
  • Shares Outstanding, K 68,251
  • Annual Sales, $ 46,020 K
  • Annual Income, $ -70,800 K
  • EBIT $ -117 M
  • EBITDA $ -117 M
  • 60-Month Beta 1.50
  • Price/Sales 13.66
  • Price/Cash Flow N/A
  • Price/Book 2.25

Options Overview Details

View History
  • Implied Volatility 73.60% ( -22.15%)
  • Historical Volatility 116.33%
  • IV Percentile 17%
  • IV Rank 14.88%
  • IV High 393.91% on 12/01/23
  • IV Low 17.61% on 07/18/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 466
  • Volume Avg (30-Day) 931
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 13,200
  • Open Int (30-Day) 12,320

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 4
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.25 +1.21%
on 11/21/24
13.98 -40.29%
on 10/28/24
-2.35 (-21.96%)
since 10/21/24
3-Month
7.61 +9.72%
on 09/10/24
13.98 -40.29%
on 10/28/24
-0.70 (-7.73%)
since 08/21/24
52-Week
5.86 +42.61%
on 11/22/23
30.99 -73.06%
on 02/08/24
+2.23 (+36.44%)
since 11/21/23

Most Recent Stories

More News
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYUâ„¢ for Diabetic Macular Edema

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

EYPT : 8.35 (-6.76%)
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EYPT : 8.35 (-6.76%)

Business Summary

EyePoint Pharmaceuticals Inc. operates as a biopharmaceutical company. It engaged in the development of drug devices to treat debilitating diseases of the eye disorders and other chronic conditions. The company's product candidate consists of DEXYCU(TM). EyePoint Pharmaceuticals Inc., formerly known...

See More

Key Turning Points

3rd Resistance Point 9.67
2nd Resistance Point 9.37
1st Resistance Point 8.86
Last Price 8.35
1st Support Level 8.05
2nd Support Level 7.74
3rd Support Level 7.23

See More

52-Week High 30.99
Fibonacci 61.8% 21.39
Fibonacci 50% 18.42
Fibonacci 38.2% 15.46
Last Price 8.35
52-Week Low 5.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar